APA (7th ed.) Citation

Garcia, J. R. (2025). A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-cell malignancies. Journal of clinical oncology, 43(16_suppl), TPS2681. https://doi.org/10.1200/JCO.2025.43.16_suppl.TPS2681

Chicago Style (17th ed.) Citation

Garcia, Jacob Randolph. "A Phase I, Multicenter, Open-label Study of UB-VV111 in Combination with Rapamycin in Relapsed/refractory CD19+ B-cell Malignancies." Journal of Clinical Oncology 43, no. 16_suppl (2025): TPS2681. https://doi.org/10.1200/JCO.2025.43.16_suppl.TPS2681.

MLA (9th ed.) Citation

Garcia, Jacob Randolph. "A Phase I, Multicenter, Open-label Study of UB-VV111 in Combination with Rapamycin in Relapsed/refractory CD19+ B-cell Malignancies." Journal of Clinical Oncology, vol. 43, no. 16_suppl, 2025, p. TPS2681, https://doi.org/10.1200/JCO.2025.43.16_suppl.TPS2681.